DEFEAT CANCER

NETRIS Pharma is dedicated to defeat cancer through novel and unique approach targeting Dependence Receptors

A Unique Environment to Develop Innovative Therapeutics

NETRIS Pharma is the first spin-off of Centre Léon Bérard and the Cancer Research Center of Lyon – CRCL – (Lyon, France) and benefits from the exceptional environment of this world’s renowned comprehensive center dedicated to cancer care, education and research.

Innovative Therapeutic Approach

By developing therapeutic products targeting a yet unexplored mechanism of cancer resistance, we offer patients novel therapeutic solutions alleviating resistance to chemotherapy, targeted therapy and immunotherapy.

Our news

01/26/2023

NETRIS Pharma Doses First Patient in Hepatocellular Carcinoma (HCC) Clinical Study with NP137

01/19/2023

NETRIS Pharma led consortium awarded €1.2 million Eurostar grant to explore netrin-1 targeted therapeutics

11/29/2022

NETRIS Pharma Doses First Patient in Phase 2 Study of NP137 for Checkpoint Inhibitor Resistance

Our publications

04/04/2022

Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer

03/11/2022

Δ40p53 isoform up-regulates netrin-1/UNC5B expression and potentiates netrin-1 pro-oncogenic activity

03/11/2022

Netrin-1 and Its Receptor DCC Are Causally Implicated in Melanoma Progression

A Strategic Focus on Intellectual Property Rights

As the world pioneer and leader biotech company targeting ligands of Dependence Receptors, NETRIS Pharma has built and is periodically reinforcing a unique portfolio of worldwide exclusive rights and patents on all key elements of its approach and activity.

Our partners

NETRIS Pharma has grown from inception with the full support of Research, Clinical and Corporate partners.

Clinical

Corporate

Research